Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($0.09), $0.05 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $13.23 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.